BCLI BRAINSTORM CELL THERAPEUTICS INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1137883 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.4%
TTM EPS YoY38.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-914.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,568.1%
Debt / equity—
Current ratio0.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-584.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $523,000 | $963,000 | $762,000 | $852,000 | $899,000 | $1.12M | $1.30M | $1.72M |
| SG&A expense | $1.09M | $2.65M | $1.28M | $1.39M | $1.15M | $1.45M | $1.78M | $1.47M |
| Operating income | -$1.61M | -$3.61M | -$2.05M | -$2.24M | -$2.05M | -$2.57M | -$3.09M | -$3.19M |
| Net income | -$1.73M | -$3.85M | -$2.13M | -$2.43M | -$2.11M | -$2.90M | -$2.86M | -$2.97M |
| EBITDA | -$1.59M | -$3.57M | -$2.01M | -$2.20M | -$2.00M | -$2.52M | -$3.04M | -$3.14M |
| EPS (basic) | -0.14 | -0.35 | -0.19 | — | -0.19 | -0.34 | -0.45 | — |
| EPS (diluted) | -0.14 | -0.35 | -0.19 | — | -0.19 | -0.34 | -0.45 | — |
| Weighted avg. shares (diluted) | 11.98M | 11.03M | 11.03M | — | 11.01M | 8.62M | 6.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $163,000 | $209,000 | $206,000 | $29,000 | $236,000 | $1.02M | $1.83M | $371,000 |
| Current assets | $453,000 | $316,000 | $184,000 | $307,000 | $508,000 | $1.51M | $2.33M | $385,000 |
| PP&E, net | $123,000 | $152,000 | $198,000 | $235,000 | $283,000 | $331,000 | $382,000 | $434,000 |
| Total assets | $840,000 | $788,000 | $755,000 | $1.02M | $1.38M | $2.57M | $3.57M | $1.83M |
| Current liabilities | $13.17M | $12.38M | $11.76M | $11.01M | $9.02M | $8.53M | $10.90M | $8.98M |
| Short-term debt | $1.88M | $1.26M | $1.33M | $967,000 | $101,000 | $101,000 | $1.20M | $300,000 |
| Total liabilities | $13.17M | $12.38M | $11.76M | $11.01M | $9.07M | $8.62M | $11.03M | $9.60M |
| Shareholders' equity | -$12.33M | -$11.60M | -$11.01M | -$9.98M | -$7.69M | -$6.06M | -$7.46M | -$7.76M |
| Shares outstanding | 14.26M | 11.03M | 11.03M | 11.03M | 11.03M | 10.12M | 7.91M | 6.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$704,000 | -$895,000 | -$1.32M | -$740,000 | -$1.10M | -$3.50M | -$1.63M | -$1.05M |
| Financing cash flow | $843,000 | $898,000 | $1.25M | $780,000 | $313,000 | $2.70M | $3.09M | $1.06M |
| Depreciation & amortization | $29,000 | $46,000 | $37,000 | $48,000 | $48,000 | $51,000 | $52,000 | $53,000 |
| Stock-based compensation | $570,000 | $2.24M | $133,000 | $143,000 | $157,000 | $503,000 | $717,000 | $208,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.